Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471685 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL21576383 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL23537845 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL25790119 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL23537846 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL29132955 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL25165408 | 0.89 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL19214839 | 0.89 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL25165591 | 0.89 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2USP2 | |
| SCHEMBL21227876 | 0.84 | NR1H2 (0.42) | CHRM2CHRM1CHRM3NR1H2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090418-A1 | PARP1 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250129051-A1 | PARP1 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4461355-A2 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4408420-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-117545748-A | Benzimidazolyl GLP-1GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023056039-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021127397-A1 | NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | CHRM2 4792/4885CHRM1 4681/4885CHRM3 4853/4885 |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | CHRM2 4822/4885CHRM1 4705/4885CHRM3 4841/4885 |
| US-20250129051-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | CHRM2 4869/4885CHRM1 4841/4885CHRM3 4835/4885 |
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | CHRM2 4822/4885CHRM1 4705/4885CHRM3 4841/4885 |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | CHRM2 1451/4885CHRM1 1194/4885CHRM3 404/4885 |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | CHRM2 1451/4885CHRM1 1194/4885CHRM3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.